Please assess the completion status of the following clinical trial:

Trial Title: Effect of Secretin in Functional Dyspepsia and Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Patients with FD and prior documentation of normal or accelerated gastric emptying and/or reduced gastric accommodation.~Inclusion criteria:~* Able to provide written informed consent prior to any study procedures and be willing and able to comply with study procedures~* No medical problems or chronic diseases, other than functional dyspepsia, for that group~* Body mass index of 18-35 kg/m2~* Female subjects must have negative urine pregnancy tests and must not be lactating prior to receiving study medication and radiation exposure. For females able to bear children, a hormonal (i.e., oral, implantable, or injectable) and single-barrier method, or a double-barrier method of birth control must be used throughout the study. Female subjects unable to bear children must have this documented in the medical record \[i.e., tubal ligation, hysterectomy, or post-menopausal (defined as a minimum of one year since the last menstrual period)\].~Exclusion criteria:~* Unable or unwilling to provide informed consent or to comply with study procedures~* Diagnosis of other gastrointestinal diseases besides functional dyspepsia~* Structural or metabolic diseases that affect the GI system~* Unable to avoid the following over-the-counter medications 48 hours prior to the baseline period and throughout the study:~  * Medications that alter GI transit or motor function including laxatives, magnesium and aluminum containing antacids, prokinetics, erythromycin, buspirone, clonidine, tricyclic antidepressants, and secretin-norepinephrine reuptake inhibitors~ * Analgesic drugs including NSAIDs and COX-2 inhibitors~ * NOTE: Stable doses of thyroid replacement, estrogen replacement, low-dose aspirin for cardio-protection, low stable dose antidepressants of the SSRI class, and birth control (but with adequate backup contraception, as drug interactions with birth control have not been conducted) are permissible.~* History of recent surgery (within 60 days of screening)~* Acute or chronic illness or history of illness which in the opinion of the investigator could pose a threat or harm to the subject or obscure interpretation of laboratory test results or interpretation of study data, such as frequent angina, Class III or IV congestive heart failure, moderate impairment of renal or hepatic function, poorly controlled diabetes, etc.~* Any clinically significant abnormalities on physical examination or laboratory abnormalities identified in the medical record, as determined by the investigator~* Acute GI illness within 48 hours of initiation of the baseline period~* Females who are pregnant or breastfeeding~* History of excessive alcohol use or substance abuse~* Participation in an investigational study within the 30 days prior to dosing in the present study~* Any other reason, which in the opinion of the investigator, would confound proper interpretation of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Healthy Controls: Secretin Then Placebo (Type: EXPERIMENTAL): Healthy subjects first receive human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 2.
- Healthy Controls: Placebo Then Secretin (Type: EXPERIMENTAL): Healthy subjects first receive placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 2.
- Functional Dyspepsia: Secretin Then Placebo (Type: EXPERIMENTAL): Functional Dyspepsia subjects first receive human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 2.
- Functional Dyspepsia: Placebo Then Secretin (Type: EXPERIMENTAL): Functional Dyspepsia subjects first receive placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).